AQR Capital Management LLC Boosts Stake in Inogen, Inc. (NASDAQ:INGN)

AQR Capital Management LLC grew its stake in shares of Inogen, Inc. (NASDAQ:INGN - Free Report) by 29.3% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 570,994 shares of the medical technology company's stock after purchasing an additional 129,307 shares during the quarter. AQR Capital Management LLC owned about 2.42% of Inogen worth $4,642,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Inspire Advisors LLC acquired a new stake in Inogen during the first quarter worth approximately $255,000. Vanguard Group Inc. grew its stake in shares of Inogen by 4.9% during the first quarter. Vanguard Group Inc. now owns 1,424,026 shares of the medical technology company's stock worth $11,492,000 after buying an additional 65,954 shares during the last quarter. Divisadero Street Capital Management LP increased its holdings in shares of Inogen by 682.3% during the second quarter. Divisadero Street Capital Management LP now owns 2,346,766 shares of the medical technology company's stock worth $19,079,000 after buying an additional 2,046,766 shares in the last quarter. Tocqueville Asset Management L.P. raised its position in Inogen by 27.3% in the first quarter. Tocqueville Asset Management L.P. now owns 93,350 shares of the medical technology company's stock valued at $753,000 after purchasing an additional 20,000 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC bought a new position in Inogen in the 1st quarter valued at approximately $81,000. 89.94% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently issued reports on INGN. Needham & Company LLC reaffirmed a "hold" rating on shares of Inogen in a research report on Wednesday, August 7th. StockNews.com raised shares of Inogen from a "sell" rating to a "hold" rating in a research report on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $7.00.

Inogen Trading Down 1.4 %

Shares of INGN traded down $0.13 during trading hours on Friday, reaching $9.12. 86,013 shares of the stock traded hands, compared to its average volume of 353,762. Inogen, Inc. has a 52 week low of $4.13 and a 52 week high of $13.33. The stock has a fifty day simple moving average of $11.02 and a 200 day simple moving average of $9.06. The company has a market cap of $215.02 million, a price-to-earnings ratio of -2.20 and a beta of 1.04.

Inogen (NASDAQ:INGN - Get Free Report) last announced its earnings results on Tuesday, August 6th. The medical technology company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.55) by $0.31. The firm had revenue of $88.77 million for the quarter, compared to the consensus estimate of $82.50 million. Inogen had a negative return on equity of 45.37% and a negative net margin of 28.30%. The company's revenue was up 6.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.42) EPS. Analysts predict that Inogen, Inc. will post -1.92 earnings per share for the current fiscal year.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.